By the instalment of the position as Chief Technical Officer and by the recruitment of Dennis Henriksen, the company strengthens its in-house competence and resources within the areas of regulatory affairs, clinical trials, production planning and intellectual property.

Dennis Henriksen (b. 1962), M.Sc. in chemical engineering from the Technical University of Copenhagen and Ph.D. in bioorganic chemistry from the University of Copenhagen, has held leading positions in biotech companies for more than 20 years. He has great experience in the processes of research, development, registration and commercialization of pharmaceuticals and has, among other positions in the past, worked as VP for BioNebraska Inc in the United States, where he was responsible for the company’s R&D. Dennis Henriksen will take up his new position with immediate effect.

“We are happy to welcome Dennis Henriksen to WntResearch. His experience and competence will strengthen the company in the preparations for the coming phase 2-study of the drug candidate Foxy-5 and in the continuing preclinical work with the drug candidate Box-5,” says Henrik Lawaetz, CEO, WntResearch.

Furthermore, WntResearch announces that Chief Medical Officer Nils Brünner has declared that he will be leaving the company by the end of 2016. Nils Brünner will turn 65 in the beginning of 2017 and with the increased workload that is associated with the preparations and implementation of the planned phase 2-study of the drug candidate Foxy-5, the company and Nils have jointly determined to start the process of finding a successor. Nils Brünner has been active in WntResearch since 2008 and has played a key role in the company’s development. He will be proposed as a new member of the company’s Board of Directors.

For further information contact:

Henrik Lawaetz, CEO
E-mail: hl@wntresearch.com
Telephone: +46 72 702 4694

About WntResearch

WntResearch is developing a new type of cancer treatment based on pioneering research, which shows that the endogenous protein Wnt-5a plays a crucial role for tumour cells’ ability to relocate and spread inside the body. Most patients that die of cancer do so not due to the primary tumour, but due to metastasises and the need for a specific treatment to counteract metastasis is therefore in high demand.

WntResearch’s most advanced drug candidate Foxy-5 has in preclinical tests been shown to reduce tumour cells’ mobility and thereby counteract the occurrence of metastasis. The results from a completed phase 1-study show a favourable security profile and pharmacokinetics as well as early indications of biological activity. A phase 1b-study is currently ongoing in patients with cancer in colon, prostate and breast. WntResearch is a public company listed at AktieTorget in Stockholm, Sweden.

For further information: www.wntresearch.com